Trial Profile
A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Pegargiminase (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms ADAM
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 21 Oct 2014 Planned End Date changed from 23 May 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov record.